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BACKGROUND: Factors associated with satisfaction
among patients receiving primary care–based bupre-
norphine/naloxone are unknown.
OBJECTIVE: To identify factors related to patient
satisfaction in patients receiving primary care–based
buprenorphine/naloxone that varied in counseling
intensity (20 vs 45 minutes) and office visit frequency
(weekly vs thrice weekly).
DESIGN AND PARTICIPANTS: One hundred and forty-
two opioid-dependent subjects.
MEASUREMENTS: Demographics, drug treatment his-
tory, and substance use status at baseline and during
treatment were collected. The primary outcome was
patient satisfaction at 12 weeks.
RESULTS: Patients’ mean overall satisfaction score was
4.4 (out of 5). Patients were most satisfied with the
medication and ancillary services and indicated strong
willingness to refer a substance-abusing friend for the
same treatment. Patients were least satisfied with their
interactions with other opioid-dependent patients,
referrals to Narcotics Anonymous, and the inconve-
nience of the treatment location. Female gender (β=.17,
P=.04) and non-White ethnicity/race (β=.17, P=.04)
independently predicted patient satisfaction. Patients
who received briefer counseling and buprenorphine/
naloxone dispensed weekly had greater satisfaction
than those whose medication was dispensed thrice
weekly (mean difference 4.9, 95% confidence interval
0.08 to 9.80, P=.03).
CONCLUSIONS: Patients are satisfied with primary care
office-based buprenorphine/naloxone. Providers should
consider the identified barriers to patient satisfaction.
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INTRODUCTION
Patientsatisfactionhasincreasinglybeenviewedasanimportant
healthcareoutcomeandhasbeenusedasameasureofqualityof
care in different health care settings, including addiction treat-
ment,
1 mental health services,
2 and primary care.
3,4 There is
limited research that examines patient satisfaction with bupre-
norphine/naloxone treatment in primary care settings or the
association between patient satisfaction and treatment outcome.
This paucity of research is particularly noteworthy given the
increasing availability and demonstrated efficacy of office-based
buprenorphine/naloxone treatment.
5–7
This study was designed to explore the satisfaction of
patients with buprenorphine/naloxone treatment in a primary
care setting. Our specific aim was to examine the association
between five classes of variables—demographics, drug treat-
ment history, baseline substance use status, treatment pro-
gram characteristics/treatment conditions, and substance use
during treatment—and patient satisfaction.
METHODS
Setting and Data Collection
The data for this study were collected as part of a 24-week
randomized clinical trial, conducted in a primary care center to
determine the efficacy of varying levels of psychosocial counsel-
ing provided with buprenorphine/naloxone maintenance in
primary care.
5 Patients received daily buprenorphine/naloxone
and were assigned to 1 of 3 treatment conditions varying in
counseling intensity (20 vs 45 minutes) and medication dis-
pensing (once weekly vs thrice weekly). Patients in standard
medical management (SMM) were dispensed buprenorphine/
naloxone either once a week (SMM-1) or thrice weekly (SMM-3),
and attended a weekly 20-minute counseling session with a
nurse and a monthly 20-minute appointment with a physician.
Patients in enhanced medical management (EMM-3) were
dispensed buprenorphine/naloxone thrice weekly and attended
a weekly 45-minute counseling session with a nurse and a
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242monthly 20-minute appointment with a physician. Of the 166
participants who enrolled in the trial, 142 completed the patient
satisfaction measure midway (week 12) during treatment.
Patient Satisfaction Questionnaire
We developed a patient satisfaction measure that assessed
domains explicated by patients in our previous clinical trials
6,8
and by Novick et al.
9 The Primary Care Buprenorphine
Satisfaction Scale (PCBSS) comprised nineteen items that
included satisfaction ratings in three areas: overall and specific
service components; staff expertise, concern, and responsive-
ness; and helpfulness of overall and specific treatment compo-
nents. PCBSS items were scored on a 5-point Likert-type scale
(possible satisfaction scores ranged from 15 to 95). Principal
component analysis results indicated that the most parsimo-
nious solution was a one-factor solution, which accounted for
37.6% of the variance. Item-total correlations ranged from 0.29
to 0.77. The 19-item scale had a Cronbach alpha of 0.89. We
correlated the total satisfaction score (obtained midway during
treatment) with weeks in treatments (r=.22, P=.007) to obtain
an estimate of the measure’s predictive validity.
Potential Correlates of Patient Satisfaction
We considered demographics (i.e., gender, ethnicity/race [White,
African-American, Hispanic], age, employment [yes/no], marital
status [yes/no], monthly income, and education [<high school,
≥high school]), drug treatment history (i.e., prior methadone
maintenance, years of methadone maintenance, and prior drug
detoxification), baseline substance use status (i.e., alcohol,
cocaine, and illicit opiate frequency; injection drug use status
[yes/no]; and prescription opioid use only [yes/no]), treatment
program characteristics/treatment conditions (which varied in
intensity of counseling and frequency of buprenorphine/nalox-
one dispensing), and substance use during treatment as poten-
tial correlates of patient satisfaction. Demographic information
and drug treatment history were collected at baseline by self-
report; baseline substance use status was assessed via self-
report and urinalysis. Illicit substance use during treatment was
measured bymeans of weekly patient self-report ofthe frequency
of drug use and the weekly urinalysis.
Data Analysis
We examined group differences on satisfaction using analysis
of variance or t tests. Pairwise comparisons were performed
using Scheffe post hoc tests. We also examined demographic
and substance use during treatment variables (univariate
correlates of patient satisfaction with a P value <.20) as
predictors of participants’ dimensional score reflecting patient
satisfaction using a simultaneous multiple regression, control-
ling for treatment condition assignment. We used the overall
PCBSS score to examine patient satisfaction.
RESULTS
Description of the Study Sample
Table 1 summarizes descriptive characteristics of the study
sample and correlations between study sample characteristics
and patient satisfaction.
Description of Patient Satisfaction
Table 2 summarizes initial descriptive characteristics of the
PCBSS, including means and standard deviations. Patients
were satisfied with their primary care buprenorphine/naloxone
treatment: their mean satisfaction ratings for overall satisfac-
tion, overall and specific service components, staff expertise,
concern, and responsiveness, and helpfulness of overall and
specific treatment components were all greater than 4.
With regard to overall and specific service components, the
highest rated satisfaction items were the treatment that partici-
pants had received in the primary care center and the courte-
ousness of staff members (both had mean ratings of 4.7). The
lowestratedsatisfactionitemswereinteractionwithotheropioid-
dependent patients and the convenience of the primary care
location, which had mean ratings of 2.9 and 3.7, respectively.
With regard to the helpfulness of overall and specific
treatment components, the highest rated satisfaction items
related to the primary care services in helping patients to cope
better with drug abuse problems, the buprenorphine/nalox-
one medication, and the perception of being treated like a
patient rather than a drug addict, which had mean ratings of
4.8, 4.8, and 4.6, respectively. The lowest rated item concerned
the helpfulness of referrals to Narcotics Anonymous or other
self-help groups, which had a mean rating of 3.2.
Factors Associated with Patient Satisfaction
In univariate analyses, overall patient satisfaction was signif-
icantly associated with sex, race, and the percentage of opiate-
free urine tests during treatment but was not associated with
drug treatment history or baseline substance use status.
Non-White participants reported significantly greater patient
Table 1. Description of the Study Sample and Correlations Between
Study Sample Characteristics and Patient Satisfaction (N=142)
Number (%) or
Mean ± SD
R P Value
Demographics
Male (%) 114 (80.3) .17 .04
White ethnicity/race* 109 (76.8) −.22 .01
Full-time employment 85 (59.9) .03 .77
Age 35.8±9.2 .15 .08
Never married 80 (56.4) −.03 .78
Monthly income in dollars 1354±1480 .04 .61
≥High school education 116 (81.7) −.09 .25
Years of opioid dependence 7.8±7.8
Days of alcohol use in last
30 days
2.9±5.4 −.03 .75
Days of cocaine use in last
30 days
1.6±3.2 .02 .84
Drug treatment history
Prior methadone
maintenance
92 (64.8) −.05 .59
Years of methadone
maintenance
2.7±2.3 −.01 .98
Prior drug detoxification 92 (64.8) .08 .34
Baseline substance use status
Injection drug use 41 (28.8) −.08 .38
Prescription drug use only 25 (17.6) .04 .66
Items in bold have P values < .20.
*White ethnicity/race was scored as 0=non-White, 1=White.
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treatment outcomes did not vary significantly by treatment
condition,
5 patient satisfaction did (F[2, 139]=3.16, P=.03).
The SMM-1 treatment group had significantly higher patient
satisfaction than the SMM-3 treatment group (mean differ-
ence 4.9, 95% confidence interval [CI] 0.08 to 9.80, P= .03)
but did not differ significantly from the EMM-3 treatment
group (mean difference 2.6, 95% CI −2.22 to 7.39, P=.42).
Although the EMM-3 treatment group reported higher
satisfaction than the SMM-3 treatment group (mean differ-
ence 2.4, 95% CI −2.43 to 7.14, P=.48), it was not at a level of
statistical significance (P=.48).
Predictors of Patient Satisfaction
A simultaneous multiple regression to determine the joint and
independent contributions of the specific variables to predict-
ing the strength of patient satisfaction revealed a significant
relationship for the overall sample (R
2=.16 [R=.40]; F[7, 134]=
3.59, P=.001 [Adjusted R
2=.11]). Significant standardized
regression coefficients were found for female gender (β=.17
[P=.04]) and non-White ethnicity/race (β=.17 [P=.04]), indi-
cating that these variables were significantly associated with
greater patient satisfaction.
DISCUSSION
This study, to our knowledge, is among the first to examine
patient satisfaction in buprenorphine/naloxone-maintained
patients in a primary care office-based setting. Overall,
patients reported high levels of satisfaction with this treat-
ment, including overall and specific service components; staff
expertise, concern, and responsiveness; and helpfulness of
overall and specific treatment components. Women reported
greater satisfaction than men and non-White participants
reported greater satisfaction than Whites. Female gender and
non-White ethnicity/race were significant independent predic-
tors of patient satisfaction even after controlling for other
baseline factors. Patients who received buprenorphine/nalox-
one weekly (SMM-1) had higher satisfaction than those who
received it thrice weekly (SMM-3).
These findings extend those reported in a recent study
concerning the acceptance of office-based agonist treatment
among primary care providers.
10 Our findings of high patient
satisfaction support the role of office-based buprenorphine/
naloxone treatment, a relatively new treatment option in the
United States, in increasing access to opioid-agonist therapy.
Buprenorphine/naloxone treatment appears to be accepted
by patients who are new to opioid-agonist treatment and those
who have previously received treatment. Furthermore, base-
line substance use status was not associated with treatment
satisfaction.
Determining the optimal level of patient contact associated
with patient satisfaction is important. Studies on community-
based drug treatment programs found that patients who spent
more time with a drug counselor reported greater satisfac-
tion,
11,12 although a different pattern of findings emerged in
our study. Specifically, patients who were assigned to the
condition with the fewest medication dispensing appointment
requirements reported the most satisfaction, even after con-
trolling for substance use during treatment. Thus, it appears
that participants were more satisfied with fewer medication
appointments and possibly more intense counseling.
Limitations to the current study are worth noting. Our use
of a single time point in treatment limits statements
concerning ongoing effects. The limited variability in patient
satisfaction scores may reflect social desirability bias; however,
it is important to note that satisfaction data were collected by
research assistants and patients were informed that their
responses were confidential. While participants’ demographic
characteristics were similar to those reported in other U.S. and
international studies of office-based buprenorphine/naloxone
maintenance, our study sample is not necessarily representa-
tive of all opioid-dependent patients.
13–15
In conclusion, this study suggests that office-based bupre-
norphine/naloxone treatment is associated with high levels of
patient satisfaction. This finding supports ongoing efforts to
expand opioid-dependent patients’ treatment options. Future
research should address factors that promote or thwart
Table 2. Means and Standard Deviations for the Primary Care
Buprenorphine Satisfaction Scale (N=142)
Patient satisfaction item Mean (SD)
Subscale 1: overall and specific service components 4.3 (0.6)
How satisfied are you with the treatment that you
have received in the Primary Care Center?*
4.7 (0.8)
Rate the PCC with respect to prompt service 4.4 (0.8)
Rate the PCC with respect to convenient
appointments
4.4 (0.8)
Rate the PCC with respect to courteous staff 4.7 (0.6)
Rate the PCC with respect to clinic comfort 4.1 (0.9)
Rate the PCC with respect to quality of care 4.3 (0.8)
Rate the PCC with respect to convenience of location 3.7 (1.2)
Rate the PCC with respect to interaction with other
patients*
2.9 (1.5)
Subscale 2: staff expertise, concern, and
responsiveness subscale
4.5 (0.5)
How well do the physician and nursing staff seem to
understand your substance abuse problem?
4.3 (0.7)
How competent and knowledgeable do the physician
and nursing staff seem to be about treating your
substance abuse problem?
4.2 (0.7)
How interested is the physician and nursing staff in
helping you with your substance abuse problem?
4.6 (0.6)
If a friend needed similar treatment for a substance
abuse problem, would you recommend the PCC to
him or her?
4.8 (0.4)
How responsive was the physician to your requests
for treatment?
4.7 (0.7)
How concerned is the physician about you as a
patient?
4.7 (0.7)
Subscale 3: helpfulness of overall and specific
treatment components
4.3 (0.7)
Have the services you received helped you deal more
effectively with your drug problem? Rate how
helpful each of the following has been for you?
4.8 (0.4)
Medication 4.8 (0.6)
Talking about my problems with the doctor 4.2 (1.1)
Talking about my problems with the nurse 4.3 (1.0)
Being treated like a patient instead of a drug addict 4.6 (0.7)
Referral to Narcotic Anonymous 3.2 (1.6)
Monitoring of drug use 4.2 (1.1)
Overall satisfaction score 4.4 (0.5) or
82.7 (9.6)
SD = standard deviation, PCC = Primary Care Center.
*These items were omitted from the overall patient satisfaction score.
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phine/naloxone treatment to ensure that its expansion is not
impeded.
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